Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genvoya for Acute HIV Infection
NCT03877536Withdrawn
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- Mar 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Primary endpoints: Plasma viral load at 96 weeks, Drug-related Adverse Events and Serious Adverse Events at 96 weeks and 1 more. Planned start Mar 2019; status: withdrawn.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03877536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877536.